References
- Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med.347, 1825–1833 (2002).
- Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med.347, 1834–1840 (2002).
- Roy D, Talajic M, Nattel S et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med.358, 2667–2677 (2008).
- Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol.41, 1690–1696 (2003).
- Steinberg JS, Sadaniantz A, Kron J et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation109, 1973–1980 (2004).
- Olsson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) program J. Am. Coll. Cardiol.47, 1997–2004 (2006).
- Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J. Am. Coll. Cardiol.48, 854–906 (2006).
- Hohnloser SH, Crijns HJ, van Eickels M et al.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med.360, 668–678 (2009).
- Connolly SJ, Crijns HJ, Torp-Pedersen C et al.; ATHENA Investigators. Analysis of stroke in ATHENA: a Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. Circulation120, 1174–1180 (2009).
- Noheria A, Kumar A, Wylie JV Jr, Josephson ME. Catheter ablation vs. antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch. Intern. Med.168(6), 581–586 (2008).
- Hsu LF, Jais P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N. Engl. J. Med.351, 2373–2383 (2004).
- Khan MN, Jaïs P, Cummings J et al.; PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N. Engl. J. Med.359, 1778–1785 (2008).
- Wilber DJ, Pappone C, Neuzil P et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA303, 333–340 (2010).
- Asirvatham SJ, Packer DL. Managing atrial fibrillation: catheter ablation or antiarrhythmic therapy? Circ. Arrhythm. Electrophysiol.2, 599–602 (2009).